Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models.
about
Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugsTransport of insulin in modified Valia-Chien chambers and Caco-2 cell monolayers.Study on biopharmaceutics classification and oral bioavailability of a novel multikinase inhibitor NCE for cancer therapy.N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion.Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.Application of method suitability for drug permeability classification.In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.Cell-based assays using calcein acetoxymethyl ester show variation in fluorescence with treatment conditionsClinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582.The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.Effect of experimental temperature on the permeation of model diffusants across porcine buccal mucosa.Assessment of intestinal absorption of total flavones of Hippophae rhamnoides L. in rat using in situ absorption models.Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism.In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.Assessment of intestinal absorption of vitexin-2''-o-rhamnoside in hawthorn leaves flavonoids in rat using in situ and in vitro absorption models.Spray-dried oil-in-water emulsion to improve the intestinal absorption and oral bioavailability of ZLR-8, a nitric oxide-releasing derivative of diclofenac.Amorphous azithromycin with improved aqueous solubility and intestinal membrane permeability.
P2860
Q28200644-FAA49944-909F-425B-B52F-25A400330F0BQ33285618-BEB196D5-16D8-492B-8A6D-AFCB43242DCDQ33755520-F9602ED4-AB10-4D11-93CA-EE0E33A7BD31Q34725965-03DBEA1B-C511-4DE9-8AC2-55AFBDAB0EBEQ35196290-16E695BD-5FF9-46C3-B4FD-088B9E3B8908Q36088451-E5A52F05-182E-4483-B20F-48C850FA19AAQ37784730-82EEDDD8-D5A9-45D7-B597-A3403A054D23Q38469693-2B58E7D9-97B2-48D2-BBA0-083AEFB099FFQ38670412-18CE0260-5A71-4C54-A27F-88C5DDBF8399Q39739399-77EDCF2B-697B-4529-9942-0E34AECF9D95Q41987156-0F229E4E-6F57-44E3-8A27-15F5EA24302FQ41988598-DD00E43F-E048-45A2-8307-70408D284C04Q43171588-3B7E1CCA-D8B6-4F42-8FB6-E37249929C82Q43260851-B2759906-6007-42B4-B7F8-712D2C91E9D0Q43446372-DF87903F-962A-4ACD-A29B-AFD97E7D9D08Q46732398-68B144AD-9368-49AB-A77F-98D602AB9275Q51503775-B2B4B7BE-F388-4E6F-BE66-3CC75C46BCF3Q53837873-59FAEBD6-B26F-429F-9F23-9244E3B4B39C
P2860
Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Characterization of jejunal ab ...... nd in vitro absorption models.
@ast
Characterization of jejunal ab ...... nd in vitro absorption models.
@en
type
label
Characterization of jejunal ab ...... nd in vitro absorption models.
@ast
Characterization of jejunal ab ...... nd in vitro absorption models.
@en
prefLabel
Characterization of jejunal ab ...... nd in vitro absorption models.
@ast
Characterization of jejunal ab ...... nd in vitro absorption models.
@en
P2093
P1476
Characterization of jejunal ab ...... nd in vitro absorption models.
@en
P2093
Hans Lennernäs
Janet Hoogstraate
Sofia Berggren
Urban Fagerholm
P304
P356
10.1016/J.EJPS.2003.12.004
P407
P577
2004-03-01T00:00:00Z